Maggie Yuen Sells 3,000 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Maggie Yuen sold 3,000 shares of the stock in a transaction on Friday, November 21st. The shares were sold at an average price of $35.72, for a total value of $107,160.00. Following the sale, the director owned 11,371 shares of the company’s stock, valued at $406,172.12. This trade represents a 20.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

AtriCure Trading Up 0.0%

ATRC traded up $0.02 during trading on Tuesday, reaching $37.76. The company had a trading volume of 45,583 shares, compared to its average volume of 549,701. The firm’s 50-day simple moving average is $35.07 and its 200 day simple moving average is $34.16. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 3.94. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -61.89 and a beta of 1.56. AtriCure, Inc. has a 12-month low of $28.29 and a 12-month high of $43.11.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Wednesday, October 29th. The medical device company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.10. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.56%. The firm had revenue of $134.27 million during the quarter, compared to analyst estimates of $131.25 million. During the same quarter last year, the business posted ($0.17) EPS. The company’s revenue was up 15.8% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. Equities research analysts anticipate that AtriCure, Inc. will post -0.6 earnings per share for the current year.

Hedge Funds Weigh In On AtriCure

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATRC. Aster Capital Management DIFC Ltd lifted its position in shares of AtriCure by 197.1% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock worth $29,000 after acquiring an additional 538 shares during the period. Geneos Wealth Management Inc. acquired a new position in shares of AtriCure in the 2nd quarter valued at $37,000. Farther Finance Advisors LLC lifted its holdings in shares of AtriCure by 1,818.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,132 shares of the medical device company’s stock worth $40,000 after acquiring an additional 1,073 shares during the period. First Horizon Corp acquired a new stake in shares of AtriCure during the 3rd quarter valued at about $42,000. Finally, US Bancorp DE increased its stake in shares of AtriCure by 98.1% in the first quarter. US Bancorp DE now owns 1,593 shares of the medical device company’s stock valued at $51,000 after buying an additional 789 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on ATRC. Needham & Company LLC boosted their target price on shares of AtriCure from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, July 30th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. Wall Street Zen upgraded AtriCure from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, October 8th. Finally, BTIG Research set a $54.00 price target on AtriCure in a report on Wednesday, July 30th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and a consensus target price of $52.22.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.